Chronic lymphocytic leukemia (CLL) is among the most prevalent leukemias in adults, which is a disease of slowly accumulated malignant B lymphocytes. A shift in therapeutic efforts for CLL over the last 10 years has had wide-ranging impact in many cases, targeted therapies have replaced conventional chemotherapy. Among this field, Bruton’s tyrosine kinase (BTK) inhibitors have come to represent the key cornerstone of contemporary CLL therapy.

Two key BTK inhibitors currently influencing treatment are Brukinsa (Zanubrutinib) and Jaypirca (Pirtobrutinib). And while both target the same pathway, they differ significantly in their mechanism of action, as well as efficacy in resistant disease and safety profiles. In this article we will discuss these differences in depth to understand fully their impact during the management of CLL. It is always advisable to get complete details on the treatment options from your healthcare provider.

A Brief Overview of BTK Inhibition in CLL

BTK is a key enzyme in the B-cell receptor (BCR) signaling pathway, essential to B cells survival, proliferation and migration. In CLL, this pathway gets overregulated and helps cancer cells escape apoptosis, or programmed death of cells.

Inhibitors that block BTK such activity by breaking such signaling link, in turn:

• Decreasing the survival of cancer cells.
• Limiting disease progression.
• Enhancing patient-level outcome.
  

BTK inhibitors have changed CLL from a chemo-dependent disease to a disease treated with oral selective targeted therapy.

Brukinsa: A Second Generation BTK Inhibitor

Zanubrutinib is a second-generation, irreversible BTK inhibitor from Brukinsa, a second-generation irreversible BTK inhibitory agent with the potential to improve upon class II, including prior treatments such as ibrutinib. It forms covalently bound on BTK enzyme covalently causing persistent inhibition.

Key Features of Brukinsa

High Selectivity: Brukinsa was developed so as to target BTK more selectively and so reduce off-target effects like had been experienced with previous inhibitors.

Strong Clinical Efficacy: High response rates have been reported in both treatment-nave and relapsed/refractory CLL patients in clinical trials. It is very effective in people who do not have previously encountered BTK inhibitors.

Safety Profile: Brukinsa demonstrates by comparison with first-generation BTK inhibitors:

• Reduced risk of atrial fibrillation.
• Decreased cardiovascular toxicity.
• Risk tolerant adverse effects: neutropenia and upper respiratory infection.
  

Jaypirca: The Next-Generation Reversible BTK Inhibitor

Jaypirca (Pirtobrutinib) is a brand new BTK inhibitor. Not unlike Brukinsa, it is a non-covalent (reversible) inhibitor. It is not covalent with BTK enzymes.

Important features of Jaypirca

Activity in Resistant Disease:  Among Jaypirca’ s major merits is its efficacy in patients with resistance to additional BTK inhibitors. The C481 mutation will also limit the ability of irreversible inhibitors to bind well.

Broad Applicability: Jaypirca is very useful for:

• Relapsed or refractory CLL.
• Recurrently treated patients with multiple lines of therapy.
  

Safety and Tolerability: Jaypirca is generally well tolerated, although the side effects are:

• Fatigue
• Diarrhea
• Mild infections.
  

Due to its safety profile, it is a potentially therapeutic option, even at the expense of heavily pretreated patients.

Covalent vs Non-Covalent Binding – Mechanism of Action

However, one major difference that stands out in the Jaypirca vs Brukinsa comparison stems from the way that these individual drugs bind to the BTK enzyme. Brukinsa covalently (irreversibly) binds BTK at the C481 site. While offering strong and constant inhibition, that can become ineffective if mutations are introduced at the site of binding.

By contrast, Jaypirca binds reversibly and lacks a dependence on the C481 site. This enables the drug to remain active even when resistance mutations are acquired. This is the cornerstone of why Jaypirca is often given after other BTK inhibitors fall short.

Comparison of Efficacy: Brukinsa versus Jaypirca

The patient population and treatment history should be considered to assess efficacy.

Brukinsa

• Response rates are high in first line and early relapse settings.
• Durable remissions in BTK inhibitor–naïve patients.
• Strong progression-free survival outcomes.
  

Jaypirca

• Good in highly pretreated patients.
• Shows activity in BTK-resistant CLL.
• Provides an alternative treatment when all other treatments are ineffective.
  

Brukinsa has been selected for earlier lines in relation to Jaypirca versus Brukinsa, and Jaypirca is preferred in the latter, especially in resistant disease.

Safety Profile Comparison

Safety is an important consideration in selecting long-term therapy for CLL.

Brukinsa Safety Highlights

• Reduced cardiovascular risk relative to previous BTK inhibitors.
• Some risk of neutropenia and infections.
• Needs to be monitored for bleeding and cardiac events.
  

Jaypirca Safety Highlights

• Good tolerability even in advanced disease.
• Low incidence of severe cardiac side effects.
• Often mild side effects tend to include fatigue and gastrointestinal symptoms.
  

Overall, both medications are generally safer than first-generation BTK inhibitors, but Jaypirca may be of lower risk in patients who have already developed toxicity.

Resistance and sequencing therapy

Resistance is one of the major treatment problems in CLL.

Brukinsa and resistance

• Mutations leading to resistance frequently result from mutations at the BTK binding site (C481).
• As patients progress, patients may need to change to alternative therapies.
  

Jaypirca and Resistance

• Specifically designed to bypass mechanisms of resistance.
• Keeps running longer following failure of covalent BTK inhibitors.
  

This gives Jaypirca a valuable role in treatment sequencing treatment, particularly in patients who are previously treated with other focused therapies.

Clinical Decision-Making: Which One to Choose?

Choosing between Brukinsa vs. Jaypirca depends on many factors:

Utilize Brukinsa When:

• Patients are still on treatment and in the early phase of therapy.
• has no prior exposure to BTK inhibitors.
• Goal is to control longer term disease with evidence-based long-term efficacy.
  

Use Jaypirca When:

• Patient with relapsed or refractory CLL.
• Resistance to previous BTK inhibitors is present.
• Fewer treatments available.
  

Doctors typically decide which treatment they recommend based on patients’ past medical history, mutation and overall health issues.

The Next 5 To 20 Years: A Prospective Study into BTK Inhibition in CLL

The emergence of more recent BTK inhibitors such as Jaypirca is evidence that targeted cancer treatment remains a dynamic innovation. The focus of future research also is on the:

• Combination therapy (BTK inhibitors together with BCL-2 inhibitors).
• The genetic mutations which direct personal treatment.
• Minimizing long-term toxicity.
  

Further data will be collected, therapy options will adapt according to the data, leading to better health outcomes (QOL) in CLL patients.

Conclusion

The use of BTK inhibitors has changed the way in which cancer patients with chronic lymphocytic leukemia may be treated by developing new options to reduce potential toxicity of chemotherapy. There are two key developments in this class, the Brukinsa and Jaypirca, both having individual advantages. Brukinsa is very effective for early-line chemotherapy with very strong efficacy and safety compared to the older drugs. Jaypirca provides an innovative drug in the case of resistant disease in a way that eliminates the long-standing drawbacks of previous BTK inhibitors.

Characterizing what these therapies do allows for individualized treatment to a patient’s specific needs to ensure treatment effectiveness. When these therapies become a part of the personalized treatment design, they will undoubtedly contribute to improving outcomes in CLL treatment.